[ad_1]
Dhaka, Bangladesh
A Bangladeshi medical company on Sunday submitted a request to conduct clinical trials of a COVID-19 vaccine produced locally on the human body.
The Globe Biotech Limited submitted the request to the Bangladesh Medical Research Council, the country’s main autonomous health regulator under the Ministry of Health.
“We are fully prepared to conduct human body trials now after successfully completing animal trials,” said Dr Asif Mahmud, head of the company’s Molecular and Cellular Biology unit and deputy director at the Anadolu agency.
It is the only local medical company to have developed a COVID-19 vaccine, called Bongavax.
“This is another important milestone for Bangladesh as it will be the first use of a locally produced vaccine in the history of the country,” said Mahmud. “We look forward to a final government decision and look forward to the necessary support in this revolutionary development.”
The company has already signed a memorandum of understanding with the International Diarrheal Diseases Research Center based in Dhaka, Bangladesh, to conduct human trials of the vaccine.
Meanwhile, the South Asian Delta nation of 165 million people is expected to receive at least five million doses of India’s Oxford-AstraZeneca COVID-19 vaccine by January 25.
Bangladesh will receive a total of 30 million vaccines from Bharat Biotech, which produces the vaccine, in six phases.
It also plans to conduct clinical trials on a COVID-19 vaccine by Chinese Sinovac Biotech Ltd, according to Dr ABM Khurshid Alam, the country’s health chief.
Up to 527,063 infections and 7,883 deaths have been confirmed to date.
The Anadolu Agency website contains only a portion of the stories offered to subscribers in the AA News Broadcasting System (HAS), and in summary form. Please contact us for subscription options.
[ad_2]
Source link
